Challenging Patents Made More Difficult by Change In Patent Offic

For years, inter partes review, better known as IPR, gave accused infringers, competitors, and other challengers a relatively fast way to test whether a patent should have been issued in the first place. It was never exactly a walk in the park. It was more like a brisk hike in dress shoes. Still, compared with full-blown patent litigation, PTAB review often looked like the cleaner, cheaper, and more technically focused option.

That balance has shifted. A series of changes at the U.S. Patent and Trademark Office has made challenging issued patents meaningfully harder, less predictable, and more strategic than it was just a short time ago. The biggest story is not that patent challenges disappeared. They did not. The story is that the gatekeeper moved closer to the front door, got more discretion, and started asking a lot more questions before letting anyone inside.

In plain English, the Patent Office has made it easier to deny a challenge before the challenger ever gets a full merits review. That matters for tech companies, startups, manufacturers, pharmaceutical players, foreign businesses selling into the U.S., and small businesses that once viewed PTAB proceedings as an efficient way to neutralize weak patents. The practical effect is simple: if you want to knock out a patent now, you need more than a strong invalidity argument. You also need timing, positioning, policy awareness, and a very good answer to the question, “Why should the Office spend its time on this case?”

Why patent challenges mattered so much in the first place

Congress created IPR and related post-grant proceedings through the America Invents Act to give the market a targeted way to challenge questionable patents without forcing everyone into the slow-motion opera of district court litigation. The idea was not mysterious. Patent quality affects competition, pricing, investment, licensing leverage, settlement pressure, and sometimes entire product categories. When a weak patent survives long enough, it can become a tollbooth on innovation.

PTAB review became especially important because it offered specialized decision-makers and relatively compressed timelines. In many cases, district courts even stayed litigation while the Patent Trial and Appeal Board evaluated patent validity. That gave challengers a meaningful shot at reducing litigation costs and narrowing the battlefield early.

Patent owners, of course, saw things differently. Many argued that PTAB proceedings became too easy to file, too repetitive, and too disruptive to rights that had already been examined and issued. Critics called the Board overly aggressive. Supporters said it was doing exactly what it was designed to do: clean out patents that never should have been granted. Welcome to patent law, where almost every reform is either overdue or the end of civilization, depending on who is billing by the hour.

The change that reset the playing field

The recent shift started when the USPTO backed away from earlier guidance that had put some guardrails on discretionary denials. Under prior policy, petitioners had clearer arguments for getting institution even when there was parallel litigation. For example, broad Sotera-style stipulations and especially strong merits could help challengers avoid a discretionary shutdown under the well-known Fintiv framework.

Then the ground moved. In 2025, the Patent Office rescinded the 2022 memo that had softened some of the harshest effects of Fintiv. That rescission restored a broader, more flexible discretionary framework and reopened the door to denials in situations where petitioners previously felt safer. A Sotera stipulation did not vanish, but it lost its old near-magic quality. Strong merits still mattered, but they no longer operated like a golden ticket.

Two things followed from that. First, uncertainty returned. Second, the Office went further and redesigned the institution process itself. Instead of letting the same PTAB panel weigh both discretion and merits together, the USPTO introduced a bifurcated approach. Discretion comes first. If the Director, consulting with senior PTAB judges, decides the petition should be denied on discretionary grounds, the challenger may never reach the merits stage in any meaningful way.

How the new PTAB process works

Under the interim process, patent owners can file a separate brief dedicated to discretionary denial. Petitioners then get a separate opposition brief. In other words, the fight over whether the challenge should even be heard now has its own mini-litigation track. That sounds procedural, but procedure is often policy wearing a necktie.

More importantly, the Director now sits at the center of that threshold decision. If discretionary denial is deemed appropriate, the case can be stopped before a traditional three-judge PTAB panel fully addresses the merits. If denial is not appropriate, only then does the petition proceed to the standard merits-based institution analysis.

This matters because the Office has expressly said the new process is tied to workload management, consistency, and the Board’s ability to meet its deadlines. In other words, the institution decision is no longer just about whether the patent challenge looks legally strong. It is also about whether the Office thinks the challenge deserves scarce agency attention. That is a major philosophical shift. It turns institution into part legal screening, part administrative triage.

Why this makes challenging patents harder

1. More discretion means more uncertainty

The first and most obvious problem for challengers is unpredictability. When the rules are more open-ended, the institution decision becomes harder to model. Patent owners can emphasize fairness, timing, duplication, and policy concerns. Petitioners can still fight back, but the old confidence that a well-built petition would at least get a fair trip to the merits is weaker than before.

2. Timing is now brutally important

Challengers once had room to think of IPR strategy as a careful chess match. Now it can feel more like speed chess with legal invoices. If the district court case is already moving, if the record is developed, or if the patent has been sitting in the market for years without challenge, those facts can work against institution. The longer a petitioner waits, the easier it becomes for a patent owner to argue settled expectations, inefficiency, and unnecessary duplication.

3. Patent owners have a stronger early-strike weapon

A separate discretionary brief gives patent owners a cleaner chance to argue, right out of the gate, that the case should never be instituted. That is a meaningful upgrade in leverage. Instead of fighting almost entirely on invalidity, they can fight on forum choice, litigation posture, prior agency consideration, policy concerns, and administrative burden.

4. Even strong merits may not save a petition

This is the part challengers hate most. The merits still matter, but they are no longer obviously decisive at the threshold stage. A petition can be quite good and still face serious risk if the Office believes parallel litigation, age of the patent, prior consideration of the art, or broader policy concerns make institution a poor use of resources.

5. Institution denials are hard to unwind

Once the Patent Office uses discretionary denial, the challenger’s options are limited. Federal Circuit decisions have continued to reinforce how difficult it is to obtain extraordinary relief from institution denials. So the practical reality is harsh: if your petition gets bounced at the door, you often stay bounced.

The new factors that widened the gatekeeper’s power

The March 2025 process did not merely rearrange the furniture. It expanded what parties could argue in discretionary briefing. The Office signaled openness to factors such as whether another forum has already addressed validity, whether the law has changed since the patent issued, the strength of the challenge, the petition’s reliance on expert testimony, the settled expectations of the parties, and compelling economic, public health, or national security interests.

That list is important because it broadens the conversation beyond classic Fintiv disputes over trial dates and overlap. It lets parties frame institution as part of a bigger policy debate. That is usually good news for the party trying to preserve the status quo, which in these cases is often the patent owner.

Then came another development in 2026. The USPTO announced additional discretionary considerations tied to American manufacturing operations, investment, and small-business use of IPR and PGR proceedings. The Office said it may consider whether accused products are made in the United States or tied to domestic manufacturing investment, whether competing patent-owner products are made in the United States, and whether the petitioner is a small business that has been sued for infringement.

That widened the lens even more. Now institution can be influenced not just by litigation posture and patent procedure, but also by economic footprint and industrial policy themes. For some patent owners, especially those able to emphasize U.S. manufacturing, this creates another persuasive layer. For some petitioners, especially foreign companies or businesses with globally distributed supply chains, it adds a new obstacle that has little to do with whether the patent should survive on the merits.

Who is most affected by the tougher patent-challenge climate?

Technology companies

Tech defendants have historically been among the most frequent PTAB users. They often face broad infringement campaigns involving patents that may be vulnerable to prior-art attacks. A system with more discretionary denial reduces the attractiveness of PTAB review as a routine defense tool, especially when there is active district court litigation moving fast.

Foreign companies selling into the U.S.

Overseas businesses may face an extra layer of friction under the 2026 manufacturing-related factors. Even if those companies have strong validity arguments, they may struggle to present the kind of U.S.-manufacturing narrative that now appears relevant to discretionary institution analysis.

Patent owners in manufacturing-heavy sectors

Patent owners with domestic production, domestic investment, and a clean narrative about protecting U.S. operations may have a more compelling anti-institution story than before. That does not guarantee victory, but it unquestionably improves the pitch.

Small businesses on both sides

Small businesses occupy a strange middle ground. Some are patent owners that benefit from stronger institutional barriers against repeated challenges. Others are accused infringers who need PTAB review because district court litigation can swallow a legal budget whole. The newer guidance does recognize a small-business petitioner factor in some situations, but it does not erase the broader trend toward a narrower front door.

What challengers must do differently now

First, file earlier whenever possible. Delay is no longer a neutral fact. It can look like gamesmanship, duplication, or disrespect for settled expectations.

Second, treat discretionary denial as a full strategic battleground, not a side issue. Petitioners need to build the record early, think through parallel proceedings, and decide whether stipulations, narrower claims, or focused grounds can reduce overlap and improve the institution narrative.

Third, coordinate legal arguments with business facts. Manufacturing footprint, supply chain details, product competition, and company size may now shape institution arguments in ways that would have sounded eccentric a few years ago. Today they are part of the script.

Fourth, stop assuming that good merits cure everything. They do not. Petitioners need a story about efficiency, fairness, timing, and why the Board’s involvement serves the public and administrative interest.

What this means for innovation and competition

Whether these changes are good policy depends heavily on your starting philosophy. Supporters say the Patent Office is finally giving patent owners relief from duplicative and abusive challenges. They argue that issued patents should not live under constant siege, especially when other forums are already handling the dispute.

Critics argue the Office is making it too hard to challenge weak patents, especially in an economy where patent assertion can pressure settlements regardless of ultimate validity. They worry that the tougher institution environment will preserve low-quality patents, raise defense costs, and make it harder for smaller innovators to clear away questionable rights.

Both sides have a point. Repetitive harassment is real. So are bad patents. The problem is that a system designed to solve one issue can easily worsen the other. When the threshold for review gets higher, the patents that most need scrutiny may be the same ones that become hardest to reach.

Experience from the field: what the tougher PTAB landscape feels like in practice

The most telling change is not found in a single memo line or briefing deadline. It shows up in how parties now experience the system. For petitioners, the process feels less like presenting a technical invalidity case and more like auditioning for permission to have that case heard. Lawyers who once focused primarily on prior art, claim charts, and expert support now spend far more time on procedural posture, litigation timing, statistics, business background, and broader policy framing. The question is no longer only, “Can we prove this patent is likely invalid?” It is also, “Can we persuade the Office that this is the right case, at the right moment, for the right reasons?”

Patent owners are experiencing a different kind of shift. Many now approach the pre-institution stage with more confidence because they have a dedicated opening to argue discretionary denial. That changes the emotional temperature of the case. The patent owner is not merely defending the merits. It is asking the Office to say the challenger should not get this forum at all. In practice, that creates a stronger early leverage point in settlement discussions, scheduling fights, and overall case posture.

In-house counsel are also feeling the change. Businesses that once treated IPR as a predictable line item in a patent-defense playbook are being forced to reevaluate assumptions. Budgeting is harder when institution odds are murkier. Executives want to know whether spending heavily on a petition still makes sense if the Board may deny review based on factors that sit outside the merits. That uncertainty can push companies toward district court defenses, earlier settlements, or narrower business compromises that they might not have accepted before.

Small companies feel the pressure especially hard. For a startup accused of infringement, PTAB review once looked like a disciplined way to test patent validity without being buried alive in litigation costs. Today, even a strong challenge may require evidence and argument touching supply chains, forum overlap, timing, and business identity. That does not make review impossible, but it does make the path more expensive and more complicated. And in patent disputes, complexity has a funny way of sending the invoice first and the clarity later.

Foreign companies and multinational manufacturers face another practical burden. Once manufacturing location and domestic investment become part of the discretionary conversation, legal teams have to coordinate with operations, finance, sourcing, and product groups on compressed deadlines. Suddenly, a PTAB strategy meeting can sound half like litigation prep and half like a manufacturing audit.

The broader experience, then, is one of compression and caution. More facts matter. More narratives matter. More doors can close early. Petitioners must prepare earlier, think broader, and accept that institution is no longer merely a technical patent screen. It is a policy-inflected gatekeeping exercise. Patent owners, meanwhile, have more room to argue that the gate should stay closed. That single change has altered the lived reality of patent challenges more than any catchy headline ever could.

Conclusion

Challenging patents has not become impossible, but it has unquestionably become harder. The modern PTAB institution fight is no longer just a contest over prior art and claim language. It is also a contest over timing, efficiency, forum overlap, workload, business context, and increasingly broader policy concerns. The Patent Office has not eliminated review. It has made access to review more conditional.

For patent owners, that is often a welcome correction. For challengers, it is a warning that the old playbook is outdated. The companies most likely to succeed now will be the ones that prepare early, build both a merits case and a discretionary case, and understand that the first battle is no longer proving the patent is weak. The first battle is convincing the Patent Office to let the challenge through the door.